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Left ventricular (LV) dysfunction is a well-established and
powerful predictor of adverse outcomes (1). Indeed, the
occurrence of severe LV systolic dysfunction (i.e., LV
ejection fraction [LVEF]35%), especially in the setting of
clinical heart failure (HF), is associated with very poor
survival if treated with medical therapy alone (2). In selected
high-risk patients with severe LV dysfunction, surgical
revascularization appears to afford a long-term survival
benefit (3–5). However, identifying which patients will
benefit from this therapeutic approach is often challenging.
In some patients with coronary artery disease (CAD), severe
LV dysfunction results from myocardial infarction (MI)
with attendant necrosis and scar formation, with or without
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ventricular remodeling. In others, severe myocardial dys-
function may be due to large areas of viable but dysfunc-
tional myocardium representing stunned (6) and/or hiber-
nating (7) myocardium, both of which would be reversible,
with the latter and, at times, the former requiring revascu-
larization. The distinction of severe LV dysfunction caused
by loss of myocardium and resultant fibrosis from severe LV
dysfunction arising from viable but dysfunctional myocar-
dium secondary to chronic hypoperfusion has important
implications for the therapeutic management of patients
with HF secondary to CAD (8). Failure to identify patients
with these potentially reversible causes of HF may lead to
progressive cellular damage, irreversible LV dysfunction,
HF, and death.
In general, evidence suggests that a survival benefit exists
for revascularization over medical therapy alone in patients
with demonstrable viability by noninvasive testing. Allman
et al. (9) recently issued a meta-analysis of 24 studies that
reported long-term patient outcomes after viability imaging
by single-photon emission computed tomography
(SPECT), positron emmission tomography (PET), or do-
butamine echocardiography in 3,088 patients (2,228 men,
860 women), with a mean EF of 32 8% and follow-up for
25  10 months. The results demonstrated that, in patients
with evidence of hibernating myocardium, a strong associ-
ation was present between revascularization and improved
outcomes, particularly in patients with severe LV dysfunc-
tion. No apparent benefit was observed for revascularization
over medical therapy in the absence of viability. In fact,
there was a trend toward higher death and nonfatal event
rates with revascularization, which could reflect the higher
procedural risk for patients with severe LV impairment
associated with the revascularization procedure itself in the
absence of a balancing clinical benefit.
The goal of viability assessment performed in the setting
of severe LV dysfunction, however, is also to identify
patients in whom revascularization can potentially improve
both symptoms and survival. In patients with HF as the
primary symptom, revascularization of relatively large areas of
viable but dysfunctional myocardium will often lead to an
improvement in regional and global LV function postoper-
atively, and subsequent improvement in symptoms and
survival (10,11).
Although the assumption that improvements in survival
would be associated with improvement in LV function after
revascularization may often be true (10), it may not apply to
all patients with low EF (12). Particularly in the presence of
severe angina, survival benefit from revascularization may
result from improvement in blood flow to myocardial areas
that are neither stunned nor hibernating but that are
supplied by severely stenotic coronary arteries. Such regions
might be expected to manifest stress-induced ischemia
before revascularization without abnormality of resting
function. Under these circumstances, revascularization of
myocardium in the distribution of the severe stenoses may
prevent subsequent fatal ischemic events and lead to im-
proved clinical outcomes without improving resting LV
function. An extensive body of literature demonstrates that
patients with severe LV dysfunction, accompanied by severe
angina (with or without clinical HF) and bypassable coro-
nary arteries show a survival benefit from revascularization
compared with medical therapy alone (5). In this setting,
however, postrevascularization improvements in survival
have not been consistently associated with improvements in
resting LV function (13).
ASSESSMENT OF TISSUE VIABILITY WITH PET
The most commonly used protocol for the evaluation of
tissue viability with PET includes the assessment of regional
myocardial perfusion with [13N]-ammonia, 82Rb, or [15O]-
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water, followed by the delineation of regional glucose
uptake with [18F]-deoxyglucose (FDG) (a marker of exog-
enous glucose uptake), thereby providing an index of myo-
cardial metabolism and, thus, cell viability. Using this
approach, three distinct perfusion-metabolism patterns can
be observed in dysfunctional myocardium: 1) normal blood
flow associated with normal FDG uptake; 2) reduced blood
flow associated with preserved or enhanced FDG uptake
(so-called perfusion-metabolism mismatch, reflecting hiber-
nating myocardium); and 3) proportional reduction in blood
flow and FDG uptake (so-called perfusion-metabolism
match, reflecting scar). The experience with the combined
perfusion-FDG approach using PET or the PET-SPECT
hybrid technique (SPECT perfusion with PET FDG im-
aging) has been extensively documented in 17 studies,
including 462 patients (11). Using the patterns described in
the previous text, the average positive predictive accuracy for
predicting improved regional function after revasculariza-
tion is 76 (range, 52% to 100%), whereas the average
negative predictive accuracy is 82% (range, 67% to 100%).
Moreover, previous studies have demonstrated that the gain
in global LV EF and symptoms after revascularization is
generally related to the magnitude of viable, dysfunctional
myocardium (as determined by the PET mismatch pattern)
assessed preoperatively (11).
Importance of the current study. The study by Beanlands
et al. (14) in this issue of the Journal confirms and expands
these observations by demonstrating an inverse relationship
between the extent of scar (PET match) and the change in
LV EF after coronary artery bypass graft surgery (CABG),
even after consideration of other, confounding factors. In a
multivariable model, the scar score was a better predictor of
the change in LV EF compared with the PET mismatch
score. This is likely due to the fact that the scar score is the
mirror image of the total extent of viable myocardium (i.e.,
LV segments showing PET mismatch plus those showing
normal perfusion and metabolism), which highlights the
shortcomings of using a single measurement of viability
(e.g., PET mismatch) for predicting the degree of func-
tional recovery after revascularization. Similar predictive
accuracies could be expected by using an “index” that
combines all segmental patterns of viability into a single
global score (15). Nevertheless, the findings by Beanlands et
al. (14) are consistent with a growing body of evidence
demonstrating that estimates of the extent and transmural
degree of myocardial scar are clinically useful predictors of
functional outcome after revascularization (16).
Limitations of previous studies. Several noninvasive ap-
proaches have been proposed to predict functional recovery
in patients with LV dysfunction (17). These include the
assessment of regional myocardial blood flow and/or myo-
cardial metabolism, the delineation of cell membrane integ-
rity, the measurement of myocardial contractile reserve, and,
more recently, estimation of the amount of myocardial scar
(16,17). In general, predictions of functional recovery fol-
lowing revascularization using these approaches have been
largely based solely on the extent of dysfunctional but viable
myocardium before revascularization. The reported value of
each of these approaches to predict recovery of LV function
has been highly variable (18). The reasons for these highly
variable results remain unclear, but they are probably related
to the multifactorial influences on improvement in LV
function after revascularization. From a clinical standpoint,
it is likely that relying even on the most accurate of these
multiple indexes of tissue viability or its absence in isolation
will lead to suboptimal prediction of outcomes (19). Indeed,
it is now evident that multiple other factors—including the
presence and magnitude of stress-induced ischemia as pre-
viously noted, the stage of cellular degeneration within
viable myocytes, the degree of LV remodeling, the timing
and success of revascularization procedures, the adequacy of
the target coronary vessels, and the time after revasculariza-
tion that LV reassessment is performed—can affect func-
tional outcome after revascularization.
IMPORTANCE OF MULTIVARIABLE MODELING
The study by Beanlands et al. (14) in the current issue of the
Journal represents a significant step forward for the meth-
odologic approach applied to this field. Both the presence
and the extent of postrevascularization improvement in LV
function are the end results of multiple, confounding
factors, as mentioned in the previous text. To best study this
phenomenon, multivariable modeling can be used to adjust
for these confounders and quantify the impact of individual
variables, as carried out by Beanlands et al. (14). Their
predictive model was significantly improved by incorporat-
ing other factors not directly related to the viability assess-
ment per se, such as the presence of diabetes, patient age,
the time elapsed between the viability assessment and
CABG, and the extent of perfusion-metabolism PET
mismatch.
Eventually, this approach can be applied to derive scores
or formulas to permit estimation of individual patients’
likelihood of experiencing improvement in LV function or
survival. Although this approach can achieve a goal of
converting the “art” of predicting LV function improvement
into a “science,” this goal lies in the future, with many
hurdles yet to be leaped. Among these hurdles is the
identification of which information is needed to formulate
these estimates. For example, the final multivariable model
presented in the study by Beanlands et al. (14) explained only
36% of the variation in LV EF after CABG. That is, the scar
score (%LV), mismatch score (%LV), perfusion tracer used,
time to surgery (6 weeks), age, diabetes, previous CABG,
and tracer/mismatch interaction failed to explain two-thirds
of the postrevascularization variation in LV functional
improvement. This suggests that there is much we do not
know regarding the prediction of postrevascularization
changes in LV function. A significant portion of this
“missing information” may be explained by incorporation of
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the results of assessment of inducible ischemia, a frequent
finding in these patients.
Furthermore, these models sometimes yield insights that
are unexpected. In the study by Beanlands et al. (14), the
investigators provide examples (Table 3 of their study) of
changes in EF based on their model by using fitted values.
For example, a 10-point increase in mismatch score resulted
in a 1.99% increase in LV EF after revascularization over
that change caused by other factors when a PET tracer was
used. However, this was not the case if a SPECT perfusion
tracer was used. Indeed, the model indicated that the
postrevascularization change in LV EF would be negative;
that is, increasing amounts of perfusion-metabolism mis-
match, when measured with a SPECT perfusion agent, was
associated with progressive decreases in postrevasculariza-
tion LV EF. Whether this change in LV EF reached
statistical significance in patients tested using a SPECT
perfusion tracer was not stated in the investigators’ report.
This latter result is highly counterintuitive and is most
likely due to an artifactual mismatch related to the lack of
SPECT attenuation correction. In comparing the FDG
with perfusion results (PET or SPECT), the investigators
defined sectors that manifested 80% of maximum perfu-
sion as “normal.” With SPECT, however, in the absence of
accurate attenuation and scatter correction, portions of the
myocardium with normal flow may artifactually appear to
have 80% maximal counts. This is frequently seen in the
inferior wall and in the inferior portions of the interventric-
ular septum. These normal regions could thus be artifactu-
ally defined as having a perfusion-metabolism mismatch.
TIMING OF REVASCULARIZATION AFTER DIAGNOSING
TISSUE VIABILITY
In the study by Beanlands et al. (14), the time from viability
assessment to CABG was an important independent pre-
dictor of the change in LV EF after CABG. Prompt
revascularization of viable myocardium (within six weeks of
diagnosis) contributed to the observed improvement in LV
EF after CABG. This is in keeping with a growing body of
evidence suggesting that myocardial hibernation represents
an incomplete adaptation to ischemia, which suggests that
the precarious balance between perfusion and viability
cannot be maintained indefinitely and that myocardial
necrosis will ultimately occur if blood flow is not restored.
Biopsies taken from hibernating regions at cardiac surgery
showed structural degeneration characterized by reduced
quantities of structural proteins, loss of myofilaments, and
disorganization of the cytoskeleton, with varying degrees of
replacement fibrosis (20,21). Patients showing mild mor-
phologic changes show faster and more complete recovery of
LV function after revascularization than those with more
severe abnormalities (20). Because of delay and partial
recovery of function in the presence of more profound
myocellular abnormalities, the time point selected to assess
follow-up LV function after revascularization will also
impact on the observed presence and magnitude of change
in LV EF.
More importantly, these findings suggest that the cellular
alterations seen in stunning/hibernating myocytes (likely)
represent a continuous spectrum of severity that can con-
ceivably worsen over time as the severity of coronary
stenoses and frequency of myocardial ischemia increase,
potentially leading to worsening of LV function and/or
progressive LV remodeling and HF. Indeed, a recent study
suggests that failure to revascularize patients with relatively
large areas of dysfunctional but viable myocardium appears
to be associated with progressive LV remodeling (i.e.,
increased LV volumes and mass, and worsening LV geom-
etry) despite adequate use of angiotensin-converting enzyme
inhibitors (22). These findings are further supported by the
fact that cardiac events in patients with viable (hibernating)
myocardium tend to cluster during the early course of the
follow-up period (19). Thus, the early hazard associated
with the presence of ischemic but viable tissue suggests that
only prompt revascularization may be able to provide the
greatest functional and survival benefit.
Additional factors affecting functional recovery. Additional
factors that were not measured in the study by Beanlands et
al. (14) are also important predictors of clinical outcomes
after revascularization. Increased LV volumes and cavity size
are predictors of poor outcome in patients with severe LV
dysfunction due to CAD and who are undergoing CABG
(23,24). Importantly, these poor results in patients with
severe LV dilation are observed even in patients with severe
anginal symptoms and evidence of viability, suggesting that
progressive LV remodeling after MI may limit the benefits
of revascularization on ventricular function and survival even
if there is evidence of viable (ischemic) myocardium. Recent
evidence suggests that the magnitude of inducible ischemia
is also a powerful predictor of prognosis in patients with
severe LV dysfunction due to CAD (25). In addition, the
delineation of the amount of stress-induced ischemia may
also help differentiate ischemic from nonischemic LV dys-
function, thereby enhancing the prediction of functional
recovery after revascularization. All these parameters can be
accurately and reproducibly measured with gated myocardial
perfusion imaging with SPECT or PET. Future studies
incorporating quantitative estimates of the extent of isch-
emia and viability as well as LV volumes are warranted to
optimize clinical predictions of outcome in patients with
ischemic cardiomyopathy.
Additional important clinical factors not considered in
the study by Beanlands et al. (14) relate to the adequacy of
the target coronary vessels and the success of the revascu-
larization procedures. For a dysfunctional myocardial seg-
ment to improve function, it must be viable, and adequate
nutrient perfusion must be restored to the ischemic zone.
Inadequate revascularization due to poor distal targets or
graft closure will ultimately result in lack of functional
improvement, even if there was evidence of viability before
revascularization.
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Conclusions. In summary, predictions of improved LV
function in patients with severely reduced EF undergoing
revascularization are profoundly influenced by several im-
portant factors as delineated in the previous text, only one of
which is the extent of dysfunctional but viable myocardium.
The available data are limited as predictions of functional
recovery after revascularization have been largely based only
on the extent of viable myocardium, leaving multiple other
factors not accounted for. The work by Beanlands et al. (14)
provides us with new data demonstrating the value of a
multifactorial approach that includes clinical, demographic,
and imaging information for the prediction of recovery of
LV function in patients with low EF. Although several
important predictors of functional outcome have not been
included in their analysis, these data clearly demonstrate
that clinical predictions can be improved with models that
incorporate parameters currently known to influence func-
tional outcomes. Both the development and the validation
of comprehensive predictive models will require large, pro-
spective series of well-characterized patients undergoing
revascularization and medical therapy. The Surgical Treat-
ment for Ischemic Heart Failure (STICH) trial will offer a
unique opportunity to develop and validate many of these
predictive models, by using state-of-the-art radionuclide
imaging, including viability, stress-induced ischemia, and
assessments of ventricular function, size, and shape. Such
predictive models will likely prove to be of great clinical
value in the often difficult process of selecting patients with
LV dysfunction and HF in whom revascularization will
likely improve both the quality and quantity of life. Until
these predictive models contain the vast majority of the
information regarding the probability of improvement, this
selection of patients for revascularization will rely heavily on
both the art and the science of medicine.
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